购物车0
产品总数：60959
| 中文名称 |
MRIA9
|
|---|---|
| 英文名称 |
MRIA9
|
| 包装储存 |
Powder -20°C 3 years；4°C 2 years
|
| 产品详情 |
MRIA9 是 ATP 竞争性的、pan-SIK 和 PAK2/3 抑制剂，其对 SIK1、SIK2 和 SIK3 的 IC50 值分别为 516 nM, 180 nM 和 127 nM。
|
|---|---|
| 生物活性 |
MRIA9 is an ATP-competitive, pan Salt-Inducible kinase (SIK) and PAK2/3 inhibitor, with IC 50 values of 516 nM, 180 nM and 127 nM for SIK1, SIK2 and SIK3, respectively.
|
| 性状 |
Solid
|
| 体外研究(In Vitro) |
MRIA9 (5 μM) MRIA9 sensitizes SKOV3 cells to paclitaxel treatment through inducing pronounced apoptosis.MRIA9 (5 μM) with paclitaxel (2 nM) significantly enhances cell death in HeLa cells.MRIA9 strongly impedes centrosome function, causes mitotic spindle mispositioning in ovarian cancer cell lines, prevents the centrosome disjunction during the late G2 phase, and sensitized ovarian cancer cells and patient derived 3D-spheroids to paclitaxel treatment. has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 体内研究(In Vivo) |
MRIA9 shows high oral bioavailability (F = 75-80%). has not independently confirmed the accuracy of these methods. They are for reference only.
|
| 运输条件 |
Room temperature in continental US; may vary elsewhere.
|
| 储存方式 |
Powder -20°C 3 years；4°C 2 years
|
| 参考文献 |
[1]. Roberta Tesch, et al. Structure-Based Design of Selective Salt-Inducible Kinase Inhibitors. J Med Chem. 2021 Jun 24;64(12):8142-8160.[2]. Monika Raab, et al. The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells. Cancers 2021, 13(15), 3658.
|
| 溶解度数据 |
In Vitro: DMSO : 66.67 mg/mL (134.17 mM; Need ultrasonic)配制储备液
|
|---|
1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。
2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。
Copyright © 2025 陌孚医药 All rights reserved 未经授权禁止拷贝本站所有资料，如有违反，将追究法律责任。
沪ICP备2023012080号 | 
沪公网安备31011402010657号
扫码关注公众号
产品使用指南
